Indivior (NASDAQ:INDV) Announces Earnings Results

Indivior (NASDAQ:INDV) issued its earnings results on Thursday. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15, reports. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The company had revenue of $307.00 million during the quarter, compared to analyst estimates of $302.25 million.

Indivior Trading Up 2.6 %

NASDAQ:INDV opened at $9.00 on Friday. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. The business has a 50 day simple moving average of $10.13 and a 200 day simple moving average of $13.76. The firm has a market capitalization of $1.24 billion, a P/E ratio of 900.00 and a beta of 0.68.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Piper Sandler reiterated an “overweight” rating and set a $16.00 target price (up previously from $15.00) on shares of Indivior in a research note on Friday. Craig Hallum lowered their price objective on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 11th.

Institutional Investors Weigh In On Indivior

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Indivior by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock worth $90,081,000 after acquiring an additional 52,836 shares during the period. Cannon Global Investment Management LLC acquired a new stake in shares of Indivior in the first quarter valued at approximately $563,000. Forsta AP Fonden bought a new stake in shares of Indivior during the first quarter valued at approximately $641,000. M&G Plc acquired a new position in shares of Indivior during the first quarter worth approximately $2,518,000. Finally, Toronto Dominion Bank grew its holdings in Indivior by 58.0% in the 1st quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock worth $44,872,000 after buying an additional 769,000 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.